Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 7/20 | 0.33 |
| ▸ | IDH2 | P48735 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717640 | 0.95 | EPHX2 (0.36) | EPHX2IDH1IDH2 | |
| Hydrochloric Acid SCHEMBL15550997 | 0.92 | EPHX2 (0.35) | EPHX2IDH1IDH2 | |
| Trifluoroacetic Acid SCHEMBL18693104 | 0.78 | EPHX2 (0.38) | EPHX2IDH1IDH2 | |
| SCHEMBL12819706 | 0.74 | EPHX2 (0.36) | EPHX2IDH1IDH2 | |
| Tert-Butyl Formate SCHEMBL28116868 | 0.72 | TDP1 (0.42) | EPHX2IDH1 | |
| SCHEMBL13431718 | 0.70 | ALDH1A1 (0.38) | EPHX2IDH1IDH2 | |
| Hydrochloric Acid SCHEMBL21357568 | 0.69 | — | — | |
| SCHEMBL8229760 | 0.69 | EPHX2 (0.36) | EPHX2IDH1IDH2 | |
| Hydrochloric Acid SCHEMBL3235396 | 0.69 | ALDH1A1 (0.36) | EPHX2IDH1IDH2 | |
| SCHEMBL26487771 | 0.69 | EPHX2 (0.37) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-14 | — | — | US | disclosed |
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-07 | — | — | US | disclosed |
| EP-3892622-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-24 | — | — | EP | disclosed |
| EP-3892623-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-10 | — | — | EP | disclosed |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-27 | — | — | US | disclosed |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| EP-3892623-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892622-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116971-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | EPHX2 1131/4885IDH1 2797/4885IDH2 2228/4885 |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | EPHX2 1131/4885IDH1 2797/4885IDH2 2228/4885 |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | EPHX2 1131/4885IDH1 2797/4885IDH2 2228/4885 |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | EPHX2 1131/4885IDH1 2797/4885IDH2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.